Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis (AURONA™)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03598036
Recruitment Status : Recruiting
First Posted : July 25, 2018
Last Update Posted : July 23, 2019
Sponsor:
Information provided by (Responsible Party):
Aurinia Pharmaceuticals Inc.

Brief Summary:
Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects with Focal Segmental Glomerulosclerosis

Condition or disease Intervention/treatment Phase
Focal Segmental Glomerulosclerosis Drug: Voclosporin Phase 2

Detailed Description:
The aim of the current study to assess the efficacy of voclosporin in achieving complete or partial remission of proteinuria after 24 weeks of therapy in subjects with focal segmental glomerulosclerosis (FSGS). As well as to assess the safety and tolerability of voclosporin over 24 weeks in subjects with FSGS.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Dose-Exploration Cohort Study Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects With Focal Segmental Glomerulosclerosis
Actual Study Start Date : June 21, 2018
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : March 2020


Arm Intervention/treatment
Experimental: Voclosporin

Cohort 1:

Maximum dose of 3 capsules (7.9mg) BID

Cohort 2

Dosing to be decided based on the safety from the first 6 subjects in Cohort 1.

Drug: Voclosporin

Voclosporin softgel capsules. Approximately 10 subjects will be enrolled into Cohort 1 and take up to 3 capsules twice daily (BID).

The dose of voclosporin for Cohort 2 (approximately 10 subjects) will be determined by analysis of efficacy and safety data at Week 12 from the first 6 subjects in Cohort 1.





Primary Outcome Measures :
  1. Proportion of subjects with remission of proteinuria [ Time Frame: 24 weeks ]
    Complete remission OR Partial remission


Secondary Outcome Measures :
  1. Proportion of subjects with complete remission or partial remission of proteinuria [ Time Frame: Weeks 8 and 12 ]
    Complete remission or partial remission of proteinuria

  2. Proportion of subjects with complete remission of proteinuria [ Time Frame: Weeks 8, 12, and 24 ]
    Complete remission of proteinuria

  3. Proportion of subjects with reduction of proteinuria [ Time Frame: Weeks 8, 12, and 24 ]
    Reduction of proteinuria

  4. Proportion of subjects with partial remission of proteinuria [ Time Frame: Weeks 8, 12, and 24 ]
    Partial remission of proteinuria

  5. Time to first occurrence of complete or partial remission of proteinuria [ Time Frame: Up to 26 weeks ]
    Complete OR partial remission of proteinuria

  6. Time to first occurrence of complete remission of proteinuria [ Time Frame: Up to 26 weeks ]
    Complete remission of proteinuria

  7. Time to first occurrence of partial remission of proteinuria [ Time Frame: Up to 26 weeks ]
    Partial remission of proteinuria

  8. Time to first occurrence of 50% reduction in UPCR from baseline [ Time Frame: Up to 26 weeks ]
    50% reduction in UPCR from baseline

  9. Duration of reduced UPCR [ Time Frame: Up to 26 weeks ]
    Duration of reduced UPCR

  10. Change from baseline in UPCR [ Time Frame: Week, 2,4,8,12,18,24 ]
    Change from baseline in UPCR

  11. Proportion of subjects with a confirmed decrease from baseline in eGFR [ Time Frame: Week, 2,4,8,12,18,24 ]
    Utilizing the CKD-EPI formula

  12. Proportion of subjects with a confirmed increase in eGFR [ Time Frame: Final Visit (week 24) to second Safety Follow-up visit (Visit 10) ]
    Increase in eGFR

  13. Change in UPCR [ Time Frame: Week 24 and 26 ]
    Change in UPCR

  14. Change in eGFR [ Time Frame: Week 24 and 26 ]
    Change in eGFR

  15. Change from baseline in serum creatinine, serum albumin, and eGFR [ Time Frame: Week, 2,4,8,12,18,24 ]
    Change from baseline in serum creatinine, serum albumin, and eGFR

  16. Quality of life assessments [ Time Frame: Week 24 ]
    Mean change in Patient Reported Outcome Measurement Information System (PROMIS) measures

  17. Quality of life assessments [ Time Frame: Week 24 ]
    Change from baseline in Kidney Disease Quality of Life-Short Form (KDQOL-SF)

  18. Safety and tolerability (treatment-emergent adverse events) [ Time Frame: 24 weeks ]
    Incidence and number of treatment-emergent adverse events

  19. Renal biopsy [ Time Frame: 24 weeks ]
    Descriptive analyses of changes in histopathology will be evaluated in post treatment renal biopsies in a subset of patients



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Primary FSGS diagnosed by renal biopsy within 6 months prior to end of screening.
  2. At initial screening assessment and at last qualifying assessment during screening period prior to baseline, FSGS subjects must have urine protein creatinine ratio (UPCR) ≥2.0 mg/mg, serum albumin ≥3.2 g/dL. Subjects can be treatment-naïve or receiving steroid treatment (oral or IV) for FSGS. Subjects taking steroids must show signs of improvement in proteinuria, defined as at least a 20% improvement in UPCR from initiation of steroids to the last stability assessment prior to baseline. Subjects who have discontinued steroid treatment due to poor tolerability may be considered for the study.
  3. Stable proteinuria, renal function, and BP for at least 2 weeks prior to baseline, as assessed by the Investigator. Substantial changes in UPCR, estimated glomerular filtration rate (eGFR), and/or BP during the screening period may be due to treatments administered (e.g., ACEIs and ARBs); and, therefore, may interfere with study assessments or outcomes, or may place the subject at increased risk. These subjects must be discussed with the medical monitor prior to initiation of study treatment.

Exclusion Criteria:

  1. Clinical or histologic evidence of secondary FSGS.
  2. Histologic evidence of collapsing variant FSGS.
  3. eGFR as calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation of ≤30 mL/minute/1.73 m2 at initial screening assessment or ≤45 mL/minute/1.73 m2 at last qualifying assessment during screening period prior to baseline.
  4. Currently requiring renal dialysis (hemodialysis or peritoneal dialysis) or expected to require dialysis during the study period.
  5. Current or medical history of:

    • Congenital or acquired immunodeficiency.
    • In the opinion of the Investigator, clinically significant drug or alcohol abuse within 2 years prior to screening.
    • Malignancy within 5 years of screening, with the exception of basal and squamous cell carcinomas treated by complete excision. Subjects with cervical dysplasia that is cervical intraepithelial neoplasia 1, but have been treated with conization or loop electrosurgical excision procedure and have had a normal repeat Papanicolaou test are allowed.
    • Current or past lymphoproliferative disease or previous total lymphoid irradiation.
    • Severe viral infection (e.g., cytomegalovirus, hepatitis B virus, hepatitis C virus) within 3 months of screening, or known HIV infection. Severe viral infection is defined as active disease requiring antiviral therapy.
    • Active tuberculosis (TB) or known history of TB/evidence of old TB if not taking prophylaxis with isoniazid.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03598036


Contacts
Layout table for location contacts
Contact: Laura Lisk (44)1 753 852132 llisk@auriniapharma.com
Contact: Krista Piper (1)778 788 5577 kpiper@auriniapharma.com

  Show 19 Study Locations
Sponsors and Collaborators
Aurinia Pharmaceuticals Inc.

Publications:
Layout table for additonal information
Responsible Party: Aurinia Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT03598036     History of Changes
Other Study ID Numbers: AUR-VCS-2017-03
First Posted: July 25, 2018    Key Record Dates
Last Update Posted: July 23, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Aurinia Pharmaceuticals Inc.:
calcineurin inhibitors
Focal Segmental Glomerulosclerosis

Additional relevant MeSH terms:
Layout table for MeSH terms
Glomerulosclerosis, Focal Segmental
Glomerulonephritis
Nephritis
Kidney Diseases
Urologic Diseases
Cyclosporine
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Calcineurin Inhibitors